Experimental Study: Presentation of Quantitative Effectiveness Information to Consumers in Direct-to-Consumer (DTC) Television and Print Advertisements for Prescription Drugs

ICR 201002-0910-001

OMB: 0910-0663

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement B
2010-06-01
Supplementary Document
2010-01-12
Supporting Statement A
2010-01-12
ICR Details
0910-0663 201002-0910-001
Historical Active
HHS/FDA
Experimental Study: Presentation of Quantitative Effectiveness Information to Consumers in Direct-to-Consumer (DTC) Television and Print Advertisements for Prescription Drugs
New collection (Request for a new OMB Control Number)   No
Regular
Approved with change 06/02/2010
Retrieve Notice of Action (NOA) 02/02/2010
As a reminder, this study should not begin before 9/1/2010 due to the moratorium on household surveys that is in place for the Census.
  Inventory as of this Action Requested Previously Approved
06/30/2013 36 Months From Approved
13,500 0 0
1,755 0 0
0 0 0

The FDCA requires manufacturers, packers, and distributors who advertise prescription human and animal drugs, including biological products for humans, disclose in advertisements certain information. FDA has an interest in fostering safety and proper use of prescription drugs, an activity that engages both risks and benefits, therefore an examination of ways to improve consumers' understanding of this information is central to this regulatory task.

US Code: 21 USC 201.57 Name of Law: FD&C Act
   US Code: 21 USC 202.1(e)(5)(ii) Name of Law: FD&C act
  
None

Not associated with rulemaking

  74 FR 29490 06/22/2009
75 FR 373 01/05/2010
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 13,500 0 0 13,500 0 0
Annual Time Burden (Hours) 1,755 0 0 1,755 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a new collection of information.

$1,026,555
Yes Part B of Supporting Statement
No
Uncollected
Uncollected
No
Uncollected
Eliazabeth Berbakos 3018271482

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
02/02/2010


© 2024 OMB.report | Privacy Policy